Environmental exposure unit simulates natural seasonal birch pollen exposures while maximizing change in allergic symptoms
Cited by (0)
Disclosures: Dr Ellis reports participating in advisory boards for ALK Abello, AstraZeneca, Aralez, Bausch Health, Circassia Ltd, GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm, and Pfizer; has been a speaker for ALK Abello, Aralez, AstraZeneca, Boehringer-Ingelheim, Meda, Medexus, Mylan, Merck, Novartis, Pediapharm, Pfizer, and Takeda; has received research grants through her institution from ALK Abello, AstraZeneca, Bayer LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi; and served as an independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc., and Regeneron Pharmaceuticals, Inc. in the past. Drs DeVeaux, Ramesh, Wang, Perlee, and O'Brien and Mr Langdon are employees of and stakeholders in Regeneron Pharmaceuticals, Inc. The remaining authors have no conflicts of interest to report.
Funding: This study was funded by Regeneron Pharmaceuticals, Inc., Tarrytown, New York, in accordance with Good Publication Practice guidelines.